Furthermore, through comprehensive bioinformatics analysis, Sun et al. [127] discovered that ATM gene mutations could independently predict the OS rate of endometrial cancer, and ATM mutant tumors had a higher level of tumoral neoantigens, which represented more favorable clinical outcomes of patients treated with ICIs [128]. The gene discussed is ATM; the disease is endometrial cancer.